USA – Arbor Biotechnologies, a genome-editing company discovering and developing the next generation of genetic medicines, has announced the completion of a U$215 million Series B financing to advance the…
Read MoreArbor Biotechnologies clinches US$215 Million Series B funding to upscale precision editing therapeutics
